Exclusive: Changing pharma marketplace means new dynamics to deal with, says Mundipharma executive

11 February 2014

The pharmaceutical market is changing, says Georg Toufar, chief marketing officer of Mundipharma International, in an exclusive article for The Pharma Letter, providing some insight on how to deal with these changes.

Some refer to the evolution of “Pharma 3.0” a seismic shift in the market place that has led to a new set of market dynamics to contend with, be it rising payer expectations and patient consumerism; poor scientific productivity; or the ever increasing focus on real-world evidence of value.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical